Safeguarding against Ebola: Vaccines and therapeutics to be stockpiled for future outbreaks.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Navigating the role of the EU Health Emergency Preparedness and Response Authority (HERA) in Europe and beyond.The Lancet regional health. Europe · 2021
   Review
2. The Joint Mobile Emerging Disease Clinical Capability (JMEDICC) laboratory approach: Capabilities for high-consequence pathogen clinical research.PLoS neglected tropical diseases · 2019
   Review
3. The use of nonhuman primates in studies of noise injury and treatment.The Journal of the Acoustical Society of America · 2019
   Review
4. Ebola virus: A global public health menace: A narrative review.Journal of family medicine and primary care · 2019
   Review
5. Identification of RUVBL1 and RUVBL2 as Novel Cellular Interactors of the Ebola Virus Nucleoprotein.Viruses · 2019
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as